Medtronic reached a critical juncture last month in its quest to build the market for renal denervation, a new device-based ...

In the latest close session, Medtronic (MDT) was up +2.38% at $92.20. This change outpaced the S&P 500's 0.13% gain on the day. Elsewhere, the Dow gained 0.16%, while the tech-heavy Nasdaq lost 0.22%.

Medtronic’s stock narrative has recently shifted, as reflected in a modest rise in the consensus analyst price target from ...

Medtronic's next-generation renal denervation (RDN) catheter — developed for transradial access — now has a name, GM Jason ...

Medtronic (NYSE:MDT) underwent analysis by 15 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The table below provides a snapshot of their recent ratings, ...

With its stock down 4.5% over the past month, it is easy to disregard Medtronic (NYSE:MDT). To decide if this trend could ...

The medical-device giant is positioning its Hugo RAS system to compete with Intuitive Surgical's da Vinci systems.

Patients treated with Symplicity Spyral had significantly lower blood pressure than people who received a sham treatment ...

If you're a dividend investor, I can understand why -- because dividend-paying stocks offer a triple upside: As long as the underlying company is healthy and growing, its stock price will likely ...

On August 19th, Medtronic released its earnings report for the fiscal first quarter ended July 25th, 2025. The company's ...

After joining Medtronic as its first chief innovation officer in 2023, SVP Ken Washington says he's leaving on Nov. 14 ...